Malignant Hyperthermia When Dantrolene Is Not Readily Available

Xiaodan Gong (✉esabri.gong@foxmail.com)
Charité – Universitätsmedizin Berlin

Research Article

Keywords: malignant hyperthermia, dantrolene, mortality, enzyme, treatment

DOI: https://doi.org/10.21203/rs.3.rs-251337/v1

License: ☺️ This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background: Malignant hyperthermia is a rare but life-threatening pharmacogenetic muscle disorder characterized by abnormal hypermetabolic reactions and commonly triggered in susceptible individuals by volatile anesthetics or succinylcholine, or both. Unfortunately, the specific medicine dantrolene is not readily available in many countries including China. The aim of this study was to find the characteristics of malignant hyperthermia under the situation that dantrolene is not readily available.

Methods: The cases of malignant hyperthermia reported on the most commonly used databases in China from 1985 to 2020 were analyzed. The inclusion criteria were the MH episodes only related to anesthesia. The exclusion criteria were dubious MH episodes only caused by Ketamine administration or MH episodes irrelevant to anesthesia. Independent samples t-test and Pearson's chi-squared test were applied to assess the difference between the survived and death cases.

Results: Ninety-two cases of malignant hyperthermia reported on the most commonly used databases in China from 1985 to 2020 were analyzed. Median (IQR [range]) age was 18.5 (11.8-37.0 [0-70.0]) years. Compared with the survived cases, the death cases had higher maximum end-tidal partial pressure of CO$_2$ (P=0.033), the maximum arterial partial pressure of CO$_2$ (P=0.006), temperature first measured when the patient was first discovered abnormal (P=0.012), and maximum temperature (P<0.001). Besides, the death cases had less minimum pH (P<0.001) and higher potassium (P<0.001) and were more likely to have coagulation disorders (p=0.018). Concerning treatment, cases used furosemide (P=0.024), mannitol (P=0.029), blood purification treatment (P=0.017) had the advantage on the outcome. Creatine phosphokinase, myoglobin, and MB isoenzyme of creatine phosphokinase differed greatly among cases during the first week. 43 (46.7%) cases had congenital diseases. 12 (13.0%) cases were reported with abnormal laboratory test results or abnormal signs that are possibly relevant before anesthesia.

Conclusions: In countries that dantrolene is not readily available, early warning, diagnosis, and prompt effective therapies are crucial for MH patients to survive.

Background

Malignant hyperthermia (MH) is a rare but life-threatening pharmacogenetic muscle disorder characterized by abnormal hypermetabolic reactions and commonly triggered in susceptible individuals by volatile anesthetics or succinylcholine, or both. The incidence of MH is estimated between 1/5 000 and 1/250 000 anesthetics [1-5]. However, the real prevalence of MH susceptibility is very much higher because most people with MH-related genetic mutations never undergo any anesthesias during their lives. Indeed, the predicted genetic prevalence is reported between 1/2 000 and 1/3 000, and another study reported the prevalence may be as high as 1/400 [6-8]. Malignant hyperthermia mortality reached up to 70% before the introduction of dantrolene [9]. Another study showed the mortality rate was 64% before administration approval of dantrolene [10]. Unfortunately, the specific medicine dantrolene is not readily available in many countries. Due to low incidence, high cost, and short life span, it is quite difficult
to get dantrolene when MH episodes happen in the great majority of hospitals in China as well. In China, MH has been often mostly reported in the form of case reports. In the vast majority of cases, dantrolene was not administered. The aim of this study was to find the characteristics of MH under the situation that dantrolene is not readily available.

Methods

The keyword *malignant hyperthermia* was used to search in Wanfang Database, China National Knowledge Infrastructure, China Science and Technology Journal Database, and China Biology Medicine Database, which are the most commonly used databases in China. Exclusion criteria were dubious MH episodes only caused by Ketamine administration or MH episodes irrelevant to anesthesia.

The MH clinical grading scale (CGS) was used to qualitatively assess the probability of the MH cases. CGS score range, MH rank, and qualitative probability are shown in Table 1. Based on the scoring rule, if more than one indicator represent a single process, only count the indicator with the highest score [11]. For example, both increased creatine kinase (CK) to more than 10 000 IU after anesthetic administration without succinylcholine (15 points) and cola-colored urine after anesthetic administration (10 points) represent the same process: muscle breakdown. Therefore, an individual with the above two abnormal signs and laboratory results would have only 15 points, not 25 points. But if authors offered the ranks or CGS scores, they were directly adopted.

Table 1 Clinical grading scale

| CGS points | MH rank | MH probability                        |
|------------|---------|---------------------------------------|
| 0          | 1       | MH probability is almost never         |
| 3-9        | 2       | MH probability is unlikely             |
| 10-19      | 3       | MH probability is somewhat less than likely |
| 20-34      | 4       | MH probability is somewhat greater than likely |
| 35-49      | 5       | MH probability is very likely          |
| 50-108     | 6       | MH probability is almost certain       |

Statistical analysis was performed using SPSS v24 (IBM Corp, Armonk, NY, USA). For continuous variables, for instance, age, maximum end-tidal and arterial CO2, temperature when the patient was first discovered abnormal, etc. in which survival and death groups of variables were compared. Descriptive statistics were expressed as mean (SD) and median (IQR [range]), and independent t-test were used. For categorical variables, for instance, gender, generalized muscular rigidity, cola-colored urine, etc., Pearson’s
The chi-squared test was used to test the difference between the variables of the two groups by number (proportion). The P-value < 0.05 was considered statistically significant.

## Results

Totally 139 relevant articles were retrieved. Dubious MH episodes only caused by Ketamine administration and MH episodes irrelevant to anesthesia were ruled out. Eventually, 110 articles and 92 cases (85.2% of MH episodes relevant to anesthesia administration reported) were included in the final analysis, but not all data were recorded and reported for these 92 cases [12-121]. Therefore, some variables included less than 92 cases and some patients’ CGS points were underestimated or not estimated. 63 (68.5%) cases were MH rank 6 representing the MH probability is almost certain. 15 (16.3%) cases were MH rank 5 representing the MH probability is very likely. 4 (4.3%) cases were MH rank 4 representing the MH probability somewhat greater than likely.

### Cases sources characteristics and demographics

One hundred and ten articles and 92 cases in this study involved 13 departments (Figure 1) and different years (Figure 2). The median age was 18.5 (11.8-37.0 [0-70.0]) years. 72 (78.3%) cases were male and 20 (21.7%) cases were female (Figure 3).

### Outcomes

A total of 50 (54.3%) cases survived and 42 (45.7%) cases died. From 1985 to 2010 the mortality was 33 (54.1%) cases, whereas the mortality was down to 9 (29.0%) cases from 2011 to 2020 (Table 2). Compared with the previous phase, the mortality in the latter phase decreased nearly by half (P=0.023). Of total cases, only 8 (8.7%) cases were used dantrolene. Of the 50 survival cases excluding the 8 cases that used dantrolene, there were 29 cases with time data beginning to improve after treatment and the median (IQR [range]) time was 1.0 (0.8-2.0 [0.3-5]) hours.

### Table 2 Outcome of MH cases. Values are number (proportion).

|                                      | Survived | Death |
|--------------------------------------|----------|-------|
| total outcome between 1985 and 2010 (n=61) | 28 (45.9%) | 33 (54.1%) |
| total outcome between 2011 and 2019 (n=31) | 22 (71.0%) | 9 (29.0%) |
| outcome between 1985 and 2010 without dantrolene (n=59) | 26 (44.1%) | 33 (55.9%) |
| outcome between 2011 and 2019 without dantrolene (n=25) | 16 (64.0%) | 9 (36.0%) |
Anesthetics

Table 3 shows the frequency with which volatile anesthetics or succinylcholine, or both, were administered. Of 76 cases with anesthetics data, five cases used succinylcholine without volatile anesthetic, 17 cases used succinylcholine and volatile anesthetic, and 71 cases only used volatile anesthetic including 32 (45.1%) cases isoflurane, 19 (26.8%) cases used sevoflurane, 18 (25.4%) cases used enflurane, and 2 (2.8%) cases used halothane.

Table 3 Anesthetics of MH cases. Values are number (proportion).

| Anesthetic drug               | Frequency (n=92) |
|-------------------------------|------------------|
| Succinylcholine +, Volatile - | 5 (5.4%)         |
| Succinylcholine +, Volatile + | 17 (18.5%)       |
| Succinylcholine -, Volatile + | 54 (58.7%)       |
| unrecorded                    | 16 (17.4%)       |

The first clinical sign

Of 83 cases with time data from induction of anesthesia to first abnormal sign interval, the median (IQR [range]) time was 1.3 (0.5-2.0 [0-18]) hours. The most frequent initial signs were hypercarbia (31 (33.7%)), sinus tachycardia (23 (25.0%)), hyperthermia (18 (19.6%)), and masseter spasm (10 (10.9%)) (Table 4).

Table 4 The first clinical sign of MH cases. Values are number (proportion).
| Condition                                         | Frequency (n=92) |
|--------------------------------------------------|-----------------|
| Elevation of end tidal CO₂                       | 31 (33.7%)      |
| Sinus tachycardia                                | 23 (25.0%)      |
| Rapidly increasing temperature                   | 18 (19.6%)      |
| Masseter spasm                                   | 10 (10.9%)      |
| Unrecorded                                       | 6 (6.5%)        |
| Reduction of oxygen saturation                   | 4 (4.3%)        |
| Reduction of blood pressure                      | 4 (4.3%)        |
| Convulsion                                       | 3 (3.3%)        |
| Elevation of blood pressure                      | 3 (3.3%)        |
| Restlessness                                     | 3 (3.3%)        |
| Muscular rigidity                                | 3 (3.3%)        |
| Poor muscle relaxation effectiveness             | 3 (3.3%)        |
| Dark red blood at surgical field                 | 2 (2.2%)        |
| Elevation of muscular tension                    | 2 (2.2%)        |
| Sweating                                          | 2 (2.2%)        |
| Elevation of airway resistance                   | 2 (2.2%)        |
| Neck stiffness                                    | 2 (2.2%)        |
| Flushed face                                      | 1 (1.1%)        |
| Cyanosis of nail beds                            | 1 (1.1%)        |
| Opisthotonos                                      | 1 (1.1%)        |
| Hot soda lime canister                           | 1 (1.1%)        |
| Reduction of heart rate                          | 1 (1.1%)        |
| Depression of ST segment in ECG                  | 1 (1.1%)        |
| Cola-colored urine                               | 1 (1.1%)        |
| Excessive bleeding at surgical field             | 1 (1.1%)        |
| Muscle tremors                                   | 1 (1.1%)        |

CO₂, carbon dioxide; ECG, electrocardiograph.
Comparisons of survived and death cases

Analysis of the age, gender, history of congenital disease, clinical sign, laboratory result, treatment, and CGS scores between the survived and death cases were as follows (Table 5). Compared with the survived cases, the death cases had higher maximum end-tidal partial pressure of carbon dioxide (PCO$_2$) (P=0.033), maximum arterial PCO$_2$ (P=0.006), temperature first measured when the patient was first discovered abnormal (P=0.012), and maximum temperature (P<0.001). Besides, the death cases had less minimum pH (P<0.001) and higher potassium (P<0.001) and were more likely to have coagulation disorders (p=0.018). Concerning treatment, cases used furosemide (P=0.024), mannitol (P=0.029), blood purification treatment (P=0.017) had the advantage on the outcome.

Table 5 Comparisons of survived and death cases. Values are mean (SD), median (IQR [range]) or number (proportion).
|                                | Survived          | Death            | P value |
|--------------------------------|-------------------|------------------|---------|
| Age; y (n=92)                  | 24.2 (16.7)       | 23.1 (17.3)      | 0.756   |
| Sex; male (n=92)               | 40 (80.0%)        | 32 (76.2%)       | 0.659   |
| Combined congenital disease    | 21 (42.0%)        | 22 (52.4%)       | 0.32    |
|                                |                   |                  |         |
| First sign interval; h (n=83)  | 1.0 (0.2-2.8 [0-11.0]) | 1.5 (1.0-2.0 [0-18.0]) | 0.787   |
| Maximum end-tidal PCO$_2$; mmHg(n=39) | 85.0 (71.8-101.3 [60.0-149.0]) | 91.0 (86.0-126.5 [75.0-223.0]) | 0.033   |
| Maximum arterial PCO$_2$; mmHg(n=44) | 83.0 (73.9-99.4 [53.0-120.0]) | 101.0 (87.8-152.2 [52.8-250.0]) | 0.006   |
| T first measured; °C (n=64)    | 38.5 (38.0-39.1 [35.8-43.0]) | 39.3 (38.6-41.1 [37.0-42.5]) | 0.012   |
| Maximum T; °C (n=88)           | 40.3 (39.3-41.4 [38.3-44.5]) | 42.3 (42.0-43.1 [39.4-46]) | <0.001  |
| Maximum HR; bpm (n=65)         | 160.0 (140.0-180.0 [110.0-220.0]) | 160.0 (150.0-190.0 [120-230.0]) | 0.187   |
| Generalised muscular rigidity  | 29 (58.0%)        | 31 (73.8%)       | 0.113   |
| (n=92)                         |                   |                  |         |
| Normal BP when first discovered| 18 (36.0%)        | 8 (19.0%)        | 0.072   |
| (n=92)                         |                   |                  |         |
| Increased BP when first discovered| 1 (2.0%)        | 5 (11.9%)        | 0.055   |
| (n=92)                         |                   |                  |         |
| No drop in BP when first discovered| 19 (38.0%)      | 13 (31.0%)       | 0.48    |
| (n=92)                         |                   |                  |         |
| Cola-colored urine (n=92)      | 11 (22.0%)        | 12 (28.6%)       | 0.468   |
| Oliguria or anuria (n=92)      | 9 (18.0%)         | 13 (31.0%)       | 0.147   |
| Minimum pH (n=48)              | 7.14 (7.08-7.22 [6.81-7.40]) | 6.92 (6.79-7.05 [6.57-7.24]) | <0.001  |
| Potassium; mmol/L (n=44)       | 5.2 (4.6-5.7 [3.8-6.7]) | 7.1 (6.5-8.3 [5.7-10.1]) | <0.001  |
| Coagulation disorders (n=92)   | 11 (22.0%)        | 19 (45.2%)       | 0.018   |
| Patient used sodium bicarbonate(n=92) | 31 (62.0%)   | 30 (71.4%)       | 0.341   |
| Patient used glucocorticoid (n=92) | 35 (70.0%)      | 31 (73.8%)       | 0.686   |
| Patient used active cooling (n=92) | 42 (84.0%)      | 30 (71.4%)       | 0.145   |
| Patient used furosemide (n=92) | 32 (64.0%)        | 17 (40.5%)       | 0.024   |
|                                | Survived | Death | P-value |
|--------------------------------|----------|-------|---------|
| Patient used mannitol (n=92)   | 12 (24.0%) | 3 (7.1%) | 0.029   |
| Patient used blood purification treatment (n=92) | 13 (26.0%) | 3 (7.1%) | 0.017   |
| Clinical grading scale score; point (n=82) | 58.0 (51.0-63.0 [33.0-73.0]) | 58.0 (51.0-61.0 [33.0-73.0]) | 0.809   |

PCO<sub>2</sub>, partial pressure of carbon dioxide; T, temperature; HR, heart rate; BP, blood pressure.

Table 5 Comparisons of survived and death cases. Values are mean (SD), median (IQR [range]) or number (proportion).

**Enzymes**

Of total cases, 13 cases were recorded more enzyme data [14, 24, 27, 31, 34, 40, 53, 87, 88, 91, 95, 109, 116]. The CGS score of the patient six, eight and ten were graded by original authors. As Figures 4 to 6 shown, creatine phosphokinase (CPK), myoglobin, and creatine phosphokinase myocardial band (CPK-MB) varied greatly during the first week, and there were significant differences among these patients as well.

**History of congenital disease and abnormal characteristics before anesthesia**

43 (46.7%) cases had congenital diseases. 12 (13.0%) cases were reported with abnormal laboratory test results or abnormal signs that are possibly relevant before anesthesia. Among these cases, 6 (6.5%) cases were with increased CPK, 4 (4.3%) cases with increased alkaline phosphatase (ALP), 2 (2.2%) cases with increased CPK-MB, 1 (1.1%) cases with increased lactic dehydrogenase (LDH), and 3 (3.3%) cases were recorded with a mildly elevated body temperature of unknown origin.

**Diagnostic testing**

Of the total cases, 7 (7.6%) cases took relevant examinations and showed positive results. In three cases, the muscles of the patients were soaked in succinylcholine solutions and all of them tested positive and contracted strongly. Muscle biopsy was performed in four cases, among which one case showed hyaline degeneration in quadriceps femoris, one case with vacuolar degeneration and myolysis in quadriceps femoris, one case with severe vacuolar degeneration in striated muscle, and one case with inflammatory and degeneration in gastrocnemius muscle. In another case, as Figure 7 shown, seven members of the immediate family of the patient took the genetic testing and six members in red were tested positive and have MH susceptibility [45].

**Discussion**

Totally 110 articles and 92 cases were used from the most commonly used databases in China. Exclusion criteria were dubious MH episodes only caused by Ketamine administration or MH episodes
irrelevant to anesthesia. This study may be limited by incomplete patient data and underreporting, but analysis bias seems to be minimal because there were no significant differences between comparisons of survived and death cases.

For the incident departments, they were concentrated in departments of orthopedics, stomatology, and hepatobiliary surgery. Around half of the incident years focused on 2001-2010. The male to female of MH cases was 3.5:1. More than half of MH cases focused on the 7-18 and 19-40 demographic. In all these MH cases reported, the total mortality was 42 (45.7%), less than the mortality rate 64%-70% reported before administration of dantrolene [9, 10]. Even in the absence of dantrolene, the mortality was down to 36.0% from 2011 to 2020. In terms of anesthetics, more than half of all these cases were administered volatile anesthetic without succinylcholine, mainly including isoflurane, sevoflurane, and enflurane. Besides, the most frequent initial signs of these cases were hypercarbia, sinus tachycardia, hyperthermia, and masseter spasm.

Although there were no significant differences between comparisons of survived and death cases, some clues were still found from the analysis. From the comparisons, the death cases had higher maximum end-tidal PCO$_2$, maximum arterial PCO$_2$, temperature first measured when the patient was first discovered abnormal, maximum temperature and potassium, and had more serious metabolic acidosis and more possibility of coagulation disorders. On the treatment side, cases that used furosemide, mannitol, blood purification treatment had a significant advantage on the outcome, which showed renoprotective therapies play important roles in outcomes in these MH cases.

The 13 cases with more enzyme data were all at MH rank 6. But there were wide differences in concentration of CPK, myoglobin, and CPK-MB between these almostcerta $\in$ cases. Therefore, the low size of these enzyme value might be that they can’t be used to rule out MH episode or determine the severity of MH, which confirm the study made by Carpenter et al.[122] that different RYR1 variants vary in the severity of CPK concentration. Besides, most of the cases’ pick time was on the second day, while occasional cases were on the third, fifth, or sixth day.

Almost half of these MH cases had congenital diseases. Around one in eight of the cases had abnormal enzyme results and mildly elevated body temperature. Therefore, anesthesiologists should take precautions when there are congenital diseases, these abnormal enzyme results or abnormally elevated body temperature for unexplained reason in pre-anesthesia patients and need to avoid administering volatile anesthetics and depolarizing neuromuscular blocking drugs muscle relaxants and strengthen monitoring in the susceptible individuals.

MH is inherited as an autosomal dominant disorder. Seven members of the immediate family of one patient all took the genetic testing, and except for the patient’s father the other six members all tested positive and have MH susceptibility. Therefore, once MH episode happens, all family members later need to be advised to take genetic testing, and if the test is positive they are further advised to make warning
cards, bracelets, or necklaces with MH susceptible on them and carry them at all times to alert anesthesiologist, nurse anesthetists, and relevant staffs in case they need anesthesia in the future.

MH is a rare but life-threatening disorder. When body temperature is over 41 °C, disseminated intravascular coagulation (DIC) is the most common cause of death [1]. The possibility of any complication almost triples per two degrees Celsius rise in maximum body temperature [123]. The lack of dantrolene is the main limitation of MH treatment. Therefore, early warning and diagnosis and prompt effective therapies are crucial for MH patients to survive, especially in the countries that dantrolene is not readily available. There is a pressing need to establish an MH website and a telephone hotline available around the clock in China and countries that have not had these yet, and anesthesiologists, nurse anesthetists, and relevant staff are also urged to register MH episodes by real-name or anonymity. All information can be collected through the internet and directly uploaded to the national database in real-time. With the consent of those MH susceptible people, the identity information is uploaded. And the information can only be disclosed in internal systems among hospitals and related units. Once these people need to undergo anesthesia, anesthesiologists, nurse anesthetists, and relevant staff can receive alerts immediately. Besides, the need to carry out extensive publicity and education concerning MH incidence, clinical presentation, pathophysiology, diagnosis, and treatment is also urgent, not only on professionals and also ordinary people. Let as many people as possible realize the importance and seriousness. MH susceptible persons would volunteer to upload their identity information by themselves.

In conclusion, in countries that dantrolene is not readily available, early warning, diagnosis, and prompt effective therapies are crucial for MH patients to survive.

**Abbreviations**

IQR: Interquartile range

MH: Malignant hyperthermia

CGS: Clinical grading scale

CK: Creatine kinase

SD: Standard deviation

CO\(_2\): Carbon dioxide

ECG: Electrocardiograph

PCO\(_2\): Partial pressure of carbon dioxide

T: Temperature

HR: Heart rate
BP: Blood pressure

CPK: Creatine phosphokinase

CPK-MB: Creatine phosphokinase myocardial band

ALP: Alkaline phosphatase

LDH: Lactic dehydrogenase

DIC: Disseminated intravascular coagulation

**Declarations**

**Ethics approval and consent to participate:** Systematic review: not applicable.

**Informed consent:** Systematic review: not applicable.

**Consent for publication:** Systematic review: not applicable.

**Availability of data and materials:** The datasets used and analysed during the current study are available from the author on request.

**Competing interests:** The author declares that she has no competing interests.

**Funding:** Not applicable.

**Authors' contributions:** XD, first author and correspondence author: Study Design, data collection, data analysis, references review, drafting article, critical revision of the article and final approval of the version to be published.

**Acknowledgements:** Not applicable.

**Authors' information:**

1 Department of Cardiology, Charité University Medicine, Campus Virchow Klinikum, Augustenburgerplatz 1, 13353 Berlin, Germany;

2 Department of Anesthesiology, The Second Clinical Medical College, Yangtze University, Jingzhou 434020, China

**References**

1. Rosenberg H, Pollock N, Schiemann A, Bulger T, Stowell K: Malignant hyperthermia: a review. *Orphanet J Rare Dis* 2015, 10:93.
2. Ording H: **Incidence of malignant hyperthermia in Denmark.** *Anesth Analg* 1985, **64**(7):700-704.
3. Lu Z, Rosenberg H, Li G: **Prevalence of malignant hyperthermia diagnosis in hospital discharge records in California, Florida, New York, and Wisconsin.** *J Clin Anesth* 2017, **39**:10-14.
4. Halliday NJ: **Malignant hyperthermia.** *J Craniofac Surg* 2003, **14**(5):800-802.
5. Schneiderbanger D, Johanssen S, Roewer N, Schuster F: **Management of malignant hyperthermia: diagnosis and treatment.** *Ther Clin Risk Manag* 2014, **10**:355-362.
6. Riazi S, Kraeva N, Hopkins PM: **Malignant Hyperthermia in the Post-Genomics Era: New Perspectives on an Old Concept.** *Anesthesiology* 2018, **128**(1):168-180.
7. Monnier N, Krivosic-Horber R, Payen JF, Kozak-Ribbens G, Nivoche Y, Adnet P, Reyford H, Lunardi J: **Presence of two different genetic traits in malignant hyperthermia families: implication for genetic analysis, diagnosis, and incidence of malignant hyperthermia susceptibility.** *Anesthesiology* 2002, **97**(5):1067-1074.
8. Gonsalves SG, Ng D, Johnston JJ, Teer JK, Stenson PD, Cooper DN, Mullikin JC, Biesecker LG, Program NCS: **Using exome data to identify malignant hyperthermia susceptibility mutations.** *Anesthesiology* 2013, **119**(5):1043-1053.
9. Denborough M: **Malignant hyperthermia.** *Lancet* 1998, **352**(9134):1131-1136.
10. Britt BA, Kalow W: **Malignant hyperthermia: a statistical review.** *Can Anesth Soc J* 1970, **17**(4):293-315.
11. Larach MG, Localio AR, Allen GC, Denborough MA, Ellis FR, Gronert GA, Kaplan RF, Muldoon SM, Nelson TE, Ording H et al.: **A clinical grading scale to predict malignant hyperthermia susceptibility.** *Anesthesiology* 1994, **80**(4):771-779.
12. An X, Wang Q, Qiu Y, Zhu Z, Ma Z, Li X: **Rescue and nursing care of adolescent patients with scoliosis complicated by malignant hyperthermia during posterior orthopedic operations.** *Journal of Clinic Nursing's Practicality* 2018, **3**(5):121-122.
13. Bai J, Chen X: **The nursing experience of successfully treating a case of malignant hyperthermia during general anesthesia.** *Nursing Practice and Research* 2011, **8**(3):122-124.
14. Cai Y, Chen L, Chen Y: **A case of malignant hyperthermia after general anesthesia.** *Chinese Journal of Anesthesiology* 2007, **27**(6):575-576.
15. Cao G, Li J, Yan F: **Nursing of patients with malignant hyperthermia after cleft palate repair.** *Journal of Practical Medical Techniques* 2003, **10**(8):929.
16. Chen B: **A case of death of malignant hyperthermia after cleft lip operation in children.** *Chinese Journal of Anesthesiology* 1995, **15**(4):192.
17. Chen B: **A death case of sudden malignant hyperthermia during general anesthesia.** *Anthology of Medicine* 1999, **18**(5):856-857.
18. Chen B, Wang P, Xu J, Tang T: **A case report: malignant hyperthermia in general anesthesia.** *Forum of Anesthesia and Monitoring* 2010, **17**(6):462.
19. Chen H: **A case report of malignant hyperthermia.** *Chinese Community Doctors* 2005, **21**(271):49.
20. Chen H, Ling H, Yu S: A case of malignant hyperthermia during ophthalmic operation in children. Guangdong Medical Journal 2003, 24(5):456.

21. Chen L: A case of malignant hyperthermia induced by general anesthetics. Tianjin Medical Journal 1998, 26(4):254.

22. Chen Q, Gong L, Yang Q: Rescue of a patient with malignant hyperthermia in general anesthesia. Journal of Nursing (China) 2008, 15(8):35-36.

23. Chen X, Hao J: Successful treatment of malignant hyperthermia during scoliosis correction: a case report. Chinese Journal of Anesthesiology 2012, 32(3):384.

24. Chen Y, Wu J, Chen L, Yang X, Bai H: Malignant hyperthermia after general anesthesia in a child with cerebral palsy. Chinese Journal of Contemporary Pediatrics 2011, 13(1):69-70.

25. Chen Y, Zhao T, Wu H, Chen G, Huang H, Xiong L: Successful treatment of malignant hyperthermia: a case report. Journal of Clinical Anesthesiology 2014, 30(9):935-936.

26. Dai L: Analysis of one case of malignant hyperthermia induced by sevoflurane. Journal of Clinical Medical Literature 2014, 1(12):2285.

27. Deng M, Jiang X, Chen W, Zheng D, He X, Yuan H: Successful rescue of one case of suspected familial hereditary malignant hyperthermia. Journal of Clinical Anesthesiology 2020, 36(2):204-205.

28. Dong Z: Nursing of malignant hyperthermia in an operation room. Journal of Hebei Medicine 2001, 7(10):945.

29. Feng B: Treatment and nursing care of a patient with malignant hyperthermia complicated with hepatic and renal failure. Modern Nursing 2005, 11(16):1372-1373.

30. Feng J, Li L, Huang Y, Zhou Z: A death case of malignant hyperthermia during anesthesia. Journal of Tianjin Medical University 2001, 7(2):292-293.

31. Gao J, Niu J, Wu S: A case of malignant hyperthermia in anesthesia. China Journal of Emergency Resuscitation and Disaster Medicine 2007, 2(12):748-749.

32. Hou X, Ding H, Feng Q: Experience of successful treatment and nursing of a patient with malignant hyperthermia in general anesthesia. Journal of Nursing (China) 2010, 17(6A):58-59.

33. Hu J, Zhang J, Zheng T, Gao Y: Success treatment of malignant hyperthermia in strabismus correction: a case report. Chinese Journal of Anesthesiology 2010, 30(9):1152.

34. Hu J, Chen M, Zhou D, Xiao X, Xiong X, Liu Y: Malignant hyperthermia caused by intravenous anesthesia: a case report and literature review. Chinese Journal of Integrated Traditional and Western Nephrology 2012, 13(5):448-449.

35. Huang D, Zhong L, Yang D, Yu J: Rescuing experience of a patient with malignant hyperthermia. Journal of Clinical Anesthesiology 2002, 18(4):215.

36. Huang M, Zeng X: A case of malignant hyperthermia after general anesthesia of cleft lip. Journal of Dental Prevention and Treatment 1998, 6(4):29.

37. Huang S, Wang M: Emergency treatment and nursing of a patient with malignant hyperthermia during general anesthesia. Journal of Nursing (China) 2003(4):97.
38. Huang W, Zhang M, Wan Z: A case of malignant hyperthermia induced by enflurane. *Chinese Journal of Anesthesiology* 2001, 17(2):114.

39. Huang Y, Chen J, Shen W, Li M: A case of intraoperative malignant hyperthermia. *Journal of Clinical Anesthesiology* 2004, 20(6):329.

40. Ji W, Lin Z: Clinical treatment of malignant hyperthermia. *Chinese Journal of Emergency Medicine* 2012, 21(8):915-917.

41. Ke J, Yuan J, Jin F, Zhu Z, Zhou X, Xu Q, Qiu M: Treatment of a patient with malignant hyperthermia induced by general anesthesia in facial plastic surgery. *Chinese Journal of Aesthetic Medicine* 2011, 20(4):671-672.

42. Kong Q, Zhou Q: Postoperative malignant hyperthermia in children: two cases report. *Hainan Medical Journal* 2001, 12(9):70-71.

43. Lan M, Jin X: Emergency nursing of a patient with malignant hyperthermia complicated by multiple organs failure. *Chinese Journal of Practical Nursing* 2007, 23:137.

44. Li F, Tang Q, Yang H, Tang Y: Experience of clinical pharmacists participating in the rescue of malignant hyperthermia. *Central South Pharmacy* 2009, 7(9):713-714.

45. Li K, Li T, Wang Y: Successful rescue of a patient with malignant hyperthermia and analysis of family gene test results. *Perioperative Safety and Quality Assurance* 2018, 2(4):212-215.

46. Li Q, Li X, Zhou M, Yang L, Lu Z, Zhu M, Yu W: Comparison of success and failure factors in the rescue of two patients with malignant hyperthermia. *Journal of Clinical Anesthesiology* 2004, 20(11):692-693.

47. Li S, Weng X, Qiu G: Malignant hyperthermia during scoliosis correction: a case report. *Chinese Journal of Orthopedics* 2000, 20(8):510-511.

48. Li W, Yin J, Wang Y, Xu J: Malignant hyperthermia during general anesthesia in a patient with rare gene mutation. *Chinese Journal of Anesthesiology* 2016, 36(10):1272-1273.

49. Li Z, Wu T: A case of malignant hyperthermia in anesthesia. *Medical Journal of National Defending Forces in Southwest China* 2016, 26(4):465-466.

50. Lin Y, Liao Y, Cai C: Malignant hyperthermia during anesthesia: a case report. *Journal of Sichuan University (Medical Science Edition)* 2016, 47(02):231.

51. Liu D, Zhao L, Gu S, Qian Y, Wang Y, Xia R, Zhu Z, Wang J: A case of malignant hyperthermia caused by succinylcholine. *Chinese Journal of Anesthesiology* 2001, 21(2):105.

52. Liu M, Lv L, Peng Y: Three cases of postoperative malignant hyperthermia in children. *Chinese Journal of Practical Pediatrics* 1999, 14(10):628-629.

53. Liu Z, Fang L, Teng Y, Zhang F, Cui W, Yan M, Dai A: Clinical diagnosis and management of malignant hyperthermia. *Chinese Journal of Emergency Medicine* 2007, 16(10):1091-1092.

54. Lu X: Nursing of one patient with malignant hyperthermia during operation. *Modern Nursing* 2005, 11(21):1865-1866.
55. Lu Y, Ding R, Zhang L: Rescue and nursing of a patient with sudden malignant hyperthermia during operation. *Journal of Modern Nursing* 2011, 17(19):2335-2336.

56. Lu Z, Chen Y, Tang L, Ling H, Gao C, Gu M, Zhang G, Chen B: Four cases of malignant hyperthermia during general anesthesia. *Chinese Journal of Anesthesiology* 2003, 23(12):935-936.

57. Ma Y, Bai L, Wang R, Pan N: A case of malignant hyperthermia during general anesthesia. *Medical Journal of Chinese People's Liberation Army* 2009, 34(11):1385.

58. Mao Y: Clinical nursing of a case of malignant hyperthermia induced by anesthesia in threedimensional spinal orthopedics. *Journal of Frontiers of Medicine* 2014, 9(2):295-296.

59. Ouyang M, Qin Z, Chen Z, Xiao J, Liu X, Gu M: Successful treatment of explosive malignant hyperthermia in operation: a case report. *Journal of Southern Medical University* 2010, 30(11):2611-2612.

60. Pan A: Analysis of a case of malignant hyperthermia during general anesthesia. *The Journal of Medical theory and practice* 2011, 24(19):2329-2330.

61. Shao X: A case of anesthesia complicated with malignant hyperthermia. *Jiangsu Medical Journal* 2007, 33(2):126.

62. Shi P: Nursing care of a patient with malignant hyperthermia. *Chinese Journal of Nursing* 1992(7):316-317.

63. Shi Y: Nursing of a child with acute malignant hyperthermia spastic cerebral palsy during operation. *Diet and Health Care* 2018, 5(52):144.

64. Song YS, Yang J: Malignant hyperthermia. *Journal of Clinical Anesthesiology* 1985, 1(2):5-7.

65. Su Q, Jin F: Clinical nursing of a case of malignant hyperthermia induced by general anesthesia in facial plastic surgery. *Journal of Qilu Nursing* 2011, 17(20):104-105.

66. Sun Y: Rescue and nursing of a patient with rare congenital multiarticular contracture and scoliosis complicated with malignant hyperthermia during operation. *Chinese General Practice Nursing* 2016, 14(33):3561-3562.

67. Tang Y, Wang R: Nursing care of a patient with malignant hyperthermia successfully rescued during an operation. *Chinese Journal of Practical Nursing* 2004, 20(3):47.

68. Tang Z, Wang Y, Guo X, Gu x: Diagnosis and treatment of malignant hyperthermia after general anesthesia for cleft lip. *West China Journal of Stomatology* 1996, 14(1):41-44.

69. Tao T, Tian K, Zhang C, Ding H, Hou X, Zhang J, Lin C, Chen Z, Chen J, Wang R et al: Successful treatment of one case of malignant hyperthermia during cervical discectomy and fusion. *Chinese Journal of Anesthesiology* 2018, 38(12):1535-1536.

70. Tian G, Xu K, Gu J, Tao G: Successful treatment of malignant hyperthermia: a case report. *Journal of Third Military Medical University* 2014, 36(12):1290,1298.

71. Wan J: The nursing experience of a patient with sudden malignant hyperthermia under general anesthesia. In: *The 10th China Operating Room Nursing Academic Exchange and Special Lecture Conference: 2006*, 2006: 2.
72. Wan X, Wu J: **A case of intraoperative malignant hyperthermia.** *Journal of Clinical Anesthesiology* 2012, **28**(11):1144.

73. Wang B, Shen J: **Two cases from one family complicated with malignant hyperthermia during general anesthesia.** *Chinese Journal of Postgraduates of Medicine* 2018, **41**(8):757-759.

74. Wang C, Ye X, Shi X: **Early diagnosis of malignant hyperthermia and treatment in the absence of dantrolene.** *Academic Journal of Second Military Medical University* 2009, **30**(04):369-372.

75. Wang L, He M, Wang J: **Autopsy of malignant hyperthermia case.** *Chinese Journal of Clinical and Experimental Pathology* 2015, **31**(10):1196-1197.

76. Wang M, Zhang H, Sun S: **A case of intraoperative malignant hyperthermia.** *Journal of Clinical Anesthesiology* 2006, **22**(6):439.

77. Wang S: **A case of malignant hyperthermia during general anesthesia of branchial cleft cyst.** *Journal of Community Medicine* 2009, **7**(9):84-85.

78. Wang T, Qin Z: **A death case of malignant hyperthermia caused by a combination of halothane and succinylcholine chloride.** *Adverse Drug Reactions Journal* 2015, **17**(2):159-160.

79. Wang W: **Malignant hyperthermia in 3 cases of cleft lip during and after general anesthesia** *Current Physician* 1998, **3**(3):61.

80. Wang X, Cheng L, Shi Y, Wang L: **A case report of malignant hyperthermia.** *Chinese Journal of Bone Tumor and Bone Disease* 2010, **9**(6):565-566.

81. Wang X, Lu Y, Qiu Y, Wu L: **Diagnosis and treatment of malignant hyperthermia in children with congenital scoliosis.** *International Journal of Anesthesiology and Resuscitation* 2016, **37**(1):46-48.

82. Wang Y: **A death case of malignant hyperthermia during operation.** *Shanxi Clinical Medicine Journal* 1998, **7**(7):416-417.

83. Wang Y, Xiong L, Cai H: **A case of malignant hyperthermia in general anesthesia.** *Journal of Central South University (Medical Sciences)* 2006, **31**(4):613-614.

84. Wang Z, Yu W, Lu Z, Li X: **Gene expression characteristics of two patients with suspected malignant hyperthermia.** *Chinese Journal of Anesthesiology* 2003, **23**(11):875-876.

85. Wei J, Zhang J, Liang Z: **A death case of suspected malignant hyperthermia during general anesthesia.** *Journal of Clinical Anesthesiology* 2010, **26**(10):919.

86. Wu L, Ni S: **Treatment of 1 Case of Anesthetic-induced Malignant Hyperthermia and Literature Analysis.** *China Pharmacy* 2012, **23**(38):3623-3625.

87. Wu Q, Deng J: **Nursing in ICU of a patient with malignant hyperthermia in scoliosis surgery.** *Chinese General Practice Nursing* 2019, **17**(4):506-510.

88. Wu Q, Fang Y, Ran X, Fang H, li Y, Mei W: **Experience of successful treatment of a patient with malignant hyperthermia.** *Perioperative Safety and Quality Assurance* 2017, **1**(5):250-253.

89. Wu R, Li H, Liu J, Li M: **A case of malignant hyperthermia in general anesthesia.** *Journal of Logistics University of CAPF* 2014, **23**(11):960-961.
90. Xiao J, Gu M, Qin Z, Chen Z, Liang S, Ouyang M, Chen Y, Liao Z, Tang J: Successful rescue of malignant hyperthermia during operation: a case report. *Journal of Clinical Anesthesiology* 2010, **26**(6):551.

91. Xiao J, Gu M, Qin Z, Chen Z, Liang S, Ouyang M, Chen Y, Tang J: Changes of plasma protease in a patient with malignant hyperthermia and successful rescue: a case report. *Guangdong Medical Journal* 2010, **31**(8):1076.

92. Xin Q, Xu M: The nursing experience of a child with malignant hyperthermia complicated with rhabdomyolysis syndrome. *Laboratory Medicine and Clinic* 2016, **13**(Supplement):412-413.

93. Xiong J: Emergency treatment and nursing of a patient with malignant hyperthermia caused by anesthesia combined with multiple organ failure. *Nanfang Journal of Nursing* 2004, **11**(12):61.

94. Xu H, Jiang H, Huang H, Zhu Y: Emergency treatment of malignant hyperthermia during oral and maxillofacial surgery: two cases report. *China Journal of Oral and Maxillofacial Surgery* 2007, **5**(5):386-388.

95. Xu P, Ge M, Gu Q: Successful rescue of intraoperative malignant hyperthermia combined with multiple organs dysfunction: a case report. *Forum of Anesthesia and Monitoring* 2004, **11**(6):443-444.

96. Xue D, Sun L, Zhang K: Nursing cooperation of one case of suspected malignant hyperthermia after anesthesia induction. *Chinese Journal of Medical Devices* 2013, **28**(04):132-133.

97. Yang M, Yang J: Rescue and nursing of a child with malignant hyperthermia during spinal orthopedic operation. *World Latest Medicine Information* 2016, **16**(26):197-198.

98. Yang Y: The nursing experience of a patient with malignant hyperthermia during orthognathic operation. In: *Chinese oral care academia exchange and special lecture conference: 2004; 2004*: 4.

99. Yao H: Experience of nursing cooperation in the successful rescue of a patient with malignant hyperthermia. In: *The 10th China Operating Room Nursing Academic Exchange and Special Lecture Conference: 2006; 2006*: 737-738.

100. Ye Y, Peng P, Yang Y: The nursing experience of the successful rescue of a patient with sudden malignant hyperthermia during general anesthesia. *Nursing Journal of Chinese People's Liberation Army* 2004, **21**(11):90-91.

101. Yu Y: Nursing report of emergency treatment in ICU for a patient with malignant hyperthermia. *Modern Hospital* 2009, **9**(9):77-78.

102. Zeng J, Li L, Wang Z: Treatment of a case of intraoperative malignant hyperthermia. *Lingnan Modern Clinics in Surgery* 2015, **15**(2):181-184.

103. Zeng R, Zhang J, Xue J, Liu J: A case of death caused by malignant hyperthermia in anesthesia. *Journal of Henan Medical University* 1997, **32**(4):127.

104. Zhang A, Dong Q: Delayed malignant hyperthermia after general anesthesia: a case report. *Journal of North China Coal Medical University* 2002, **4**(1):97.
105. Zhang C, Zhang Y, Wang M, Wang z, Zhang A: Role of operating room nurses in the rescue of rare malignant hyperthermia during operation. *Medicine and Pharmacy of Yunnan* 2017, 38(6):651-653.

106. Zhang H, Xie H, Yan X: One death case of malignant hyperthermia after general anesthesia. *Journal of Forensic Medicine* 2008, 24(4):313-314.

107. Zhang L, Shen H, Chen S: A case report of malignant hyperthermia caused by anesthesia. *Hainan Medical Journal* 2008, 19(1):136-137.

108. Zhang S: Nursing care of a patient with malignant hyperthermia. In: *Chinese medicine nursing work experience academic exchange conference: 2002, 2002: 203-204*.

109. Zhang X: Experience in successfully treating a child with malignant hyperthermia. *Medical Information* 2015, 28(12):259.

110. Zhang X, Huang Y, Ge Z, Xu Z, Guo X, Luo A: Clinical diagnosis and management of malignant hyperthermia. *Chinese Journal of Anesthesiology* 2000, 20(8):454-455.

111. Zhang X, Yang B, Wang W, Long X, Mo Z: A neonatal case of malignant hyperthermia after anesthesia. *Chinese Journal of Pediatric Surgery* 2003, 24(4):365.

112. Zhang Y, Yu J: Pathological analysis of a death case caused by malignant hyperthermia. *Modern Practical Medicine* 2012, 24(8):887-888.

113. Zhang Z, Gao Y, Gan X, Wang L, Wang Y: Strabismus surgery and malignant hyperthermia in children. *Chinese Journal of Strabismus and Pediatric Ophthalmology* 2013, 21(4):10-11.

114. Zhao A, Li Y: The nursing experience of a patient with malignant hyperthermia during operation. *Henan Journal of Diagnosis and Therapy* 2002, 16(6):454-455.

115. Zheng M, Xu F, Xu J, Zhang Y, Jin L: A case of malignant hyperthermia successfully treated. *Chinese Journal of Anesthesiology* 2005, 25(4):248.

116. Zheng Y, Li C: Successful rescue of malignant hyperthermia during operation: a case report. *Zhejiang clinical medicine* 2018, 20(3):563-564.

117. Zhou L, Zhao L, Wang J, Xu M, Pu X: Rescue and management of a rare patient with malignant hyperthermia during operation. *Journal of Nurses Training* 2002, 17(12):949-950.

118. Zhou Y: Beware of malignant hyperthermia induced by anesthesia in cleft lip and palate operation. *China Health care and Nutrition* 2014(4):1966-1967.

119. Zhu G: Rescue and intensive care of a case of malignant hyperthermia during left cryptorchidism exploration. *Journal of Clinic Nursing’s Practicality* 2017, 2(49):160-161.

120. Zhu Y, Jiang H, Xu H, Liu H, Chen Z, Huang H: Successful resuscitation of malignant hyperthermia: two cases report. *Shanghai Medical Journal* 2005, 28(11):986-987.

121. Zuo J: A case report of successful treatment of malignant hyperthermia. *Medical Information* 2013, 26(11):208-209.

122. Carpenter D, Robinson RL, Quin nell RJ, Ringrose C, Hogg M, Casson F, Booms P, Iles DE, Halsall PJ, Steele DS et al: Genetic variation in RYR1 and malignant hyperthermia phenotypes. *Br J Anesth* 2009, 103(4):538-548.
123. Larach MG, Gronert GA, Allen GC, Brandom BW, Lehman EB: Clinical presentation, treatment, and complications of malignant hyperthermia in North America from 1987 to 2006. Anesth Analg 2010, 110(2):498-507.